

Clifford M Takemoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3751766/publications.pdf>

Version: 2024-02-01

71
papers

3,709
citations

186265
28
h-index

128289
60
g-index

72
all docs

72
docs citations

72
times ranked

5409
citing authors

#	ARTICLE	IF	CITATIONS
1	CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. <i>Blood Advances</i> , 2022, 6, 521-527.	5.2	10
2	Current and future treatment approaches for Barth syndrome. <i>Journal of Inherited Metabolic Disease</i> , 2022, 45, 17-28.	3.6	14
3	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	7.4	37
4	Introduction: The changing role of the pediatric hematologist/oncologist in the care of people with vascular anomalies. <i>Pediatric Blood and Cancer</i> , 2022, , e29614.	1.5	0
5	Thrombosis with COVID-19: kids get it too. <i>Blood</i> , 2021, 138, 109-111.	1.4	4
6	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1513.	7.4	24
7	How we approach thrombosis risk in children with COVID-19 infection and MIS-C. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29049.	1.5	25
8	Reduced intensity chemotherapy with tyrosine kinase inhibitor and blinatumomab in a pediatric patient with Philadelphia chromosome-positive ALL and mechanical heart valves. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28924.	1.5	0
9	Liposome-Encapsulated Cytarabine and Daunorubicin (CPX-351) Induces Remission in Newly Diagnosed Pediatric Secondary Myeloid Malignancies. <i>Blood</i> , 2021, 138, 4415-4415.	1.4	0
10	Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiotensin levels. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28529.	1.5	17
11	Germline Gain-of-Function <i>JAK3</i> Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells. <i>Blood</i> , 2020, 136, 9-10.	1.4	9
12	Mortality and Associated Comorbidities Among Patients Hospitalized for Deep Vein Thrombosis and Pulmonary Embolism in the United States: Results from a Nationally Representative Database. <i>Blood</i> , 2020, 136, 39-40.	1.4	3
13	Risk Factors and Cardiovascular Disease (CVD) Related Outcomes in Hospitalized Patients with Hemophilia 10 Year Follow up. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
14	Correlates of successful transition in young adults with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27939.	1.5	7
15	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 528-541.	2.3	18
16	Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome. <i>Blood</i> , 2019, 134, 1114-1114.	1.4	1
17	Diagnostic utility of telomere length testing in a hospital-based setting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2358-E2365.	7.1	165
18	Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. <i>Blood Reviews</i> , 2018, 32, 361-367.	5.7	35

#	ARTICLE	IF	CITATIONS
19	Risk factors for hospital-associated venous thromboembolism in critically ill children following cardiothoracic surgery or therapeutic cardiac catheterisation. <i>Cardiology in the Young</i> , 2018, 28, 234-242.	0.8	20
20	The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 749-754.	1.7	4
21	Diagnosis of congenital and acquired focal lesions in the neck, abdomen, and pelvis with contrast-enhanced ultrasound: a pictorial essay. <i>European Journal of Pediatrics</i> , 2018, 177, 1459-1470.	2.7	3
22	Challenges in the management of the transgender patient with sickle cell disease. <i>American Journal of Hematology</i> , 2018, 93, E360-E362.	4.1	7
23	Association of Perioperative Red Blood Cell Transfusions With Venous Thromboembolism in a North American Registry. <i>JAMA Surgery</i> , 2018, 153, 826.	4.3	133
24	Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome. <i>Journal of Neurosurgery: Pediatrics</i> , 2017, 20, 232-238.	1.3	23
25	Pediatric Hospital Acquired Venous Thromboembolism. <i>Frontiers in Pediatrics</i> , 2017, 5, 198.	1.9	37
26	High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 627-635.	0.6	11
27	Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. <i>Blood</i> , 2015, 125, 1470-1476.	1.4	184
28	Immune thrombocytopenia due to Trimethoprim-Sulfamethoxazole; under-recognized adverse drug reaction in children?. <i>Pediatric Blood and Cancer</i> , 2015, 62, 922-923.	1.5	3
29	Development of a new risk score for hospital-associated venous thromboembolism in critically-ill children not undergoing cardiothoracic surgery. <i>Thrombosis Research</i> , 2015, 136, 717-722.	1.7	50
30	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015, 47, 1326-1333.	21.4	233
31	Iron Status is Associated with Asthma and Lung Function in US Women. <i>PLoS ONE</i> , 2015, 10, e0117545.	2.5	52
32	Mortality Associated with Venous Thromboembolism in Hospitalized Pediatric Patients: A Single Tertiary Care Institute Experience. <i>Blood</i> , 2015, 126, 629-629.	1.4	10
33	First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol,) Tj ETQq1 1 0.784314 rgBT ₀ /Overlook	1.4	14
34	Computerized Physician Order Entry Improves Compliance With a Manual Exchange Transfusion Protocol in the Pediatric Intensive Care Unit. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 143-147.	0.6	13
35	Hospital-Associated Venous Thromboembolism in Children: Incidence and Clinical Characteristics. <i>Journal of Pediatrics</i> , 2014, 164, 332-338.	1.8	112
36	Development of a New Risk Score for Hospital-Associated Venous Thromboembolism in Noncritically Ill Children: Findings from a Large Single-Institutional Case-Control Study. <i>Journal of Pediatrics</i> , 2014, 165, 793-798.	1.8	60

#	ARTICLE	IF	CITATIONS
37	Risk factors for hospital-associated venous thromboembolism in the neonatal intensive care unit. <i>Thrombosis Research</i> , 2014, 134, 305-309.	1.7	59
38	Von Willebrand Disease. <i>Pediatrics in Review</i> , 2014, 35, 136-137.	0.4	0
39	Activated Partial Thromboplastin Time and Anti-Xa Measurements in Heparin Monitoring. <i>American Journal of Clinical Pathology</i> , 2013, 139, 450-456.	0.7	78
40	SHP-1 Regulation of Mast Cell Function in Allergic Inflammation and Anaphylaxis. <i>PLoS ONE</i> , 2013, 8, e55763.	2.5	19
41	A Risk-Prediction Model For Identifying Venous Thromboembolism In Hospitalized Pediatric Patients: A Single Institution Retrospective Case-Control Analysis. <i>Blood</i> , 2013, 122, 2957-2957.	1.4	2
42	Genetic Evidence for Critical Roles of P38 β Protein in Regulating Mast Cell Differentiation and Chemotaxis through Distinct Mechanisms. <i>Journal of Biological Chemistry</i> , 2012, 287, 20258-20269.	3.4	15
43	Safety and efficacy of catheter directed thrombolysis in children with deep venous thrombosis. <i>British Journal of Haematology</i> , 2012, 159, 376-378.	2.5	11
44	Venous thromboembolism in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2012, 47, 105-112.	2.0	36
45	Thrombotic disease in critically ill children. <i>Pediatric Critical Care Medicine</i> , 2011, 12, 80-89.	0.5	20
46	KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. <i>Blood</i> , 2011, 117, 3629-3640.	1.4	60
47	Heparin-Induced Thrombocytopenia Screening and Management in Pediatric Patients. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 162-169.	2.5	17
48	Balanced Interactions between Lyn, the p85 β Regulatory Subunit of Class IA Phosphatidylinositol-3-Kinase, and SHIP Are Essential for Mast Cell Growth and Maturation. <i>Molecular and Cellular Biology</i> , 2011, 31, 4052-4062.	2.3	17
49	Heparin Induced Thrombocytopenia in Pediatric Patients: Utility of Laboratory Testing. <i>Blood</i> , 2011, 118, 1171-1171.	1.4	0
50	Mast Cells – Friend or Foe?. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 342-344.	0.6	0
51	SHP-1 Deficient Mast Cells Are Hyperresponsive to Stimulation and Critical in Initiating Allergic Inflammation in the Lung. <i>Journal of Immunology</i> , 2010, 184, 1180-1190.	0.8	38
52	Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines. <i>Pediatrics</i> , 2010, 126, 746-759.	2.1	503
53	PLI.1 Positively Regulates GATA-1 Expression in Mast Cells. <i>Journal of Immunology</i> , 2010, 184, 4349-4361.	0.8	14
54	D-dimer for the diagnosis of venous thromboembolism in children. <i>American Journal of Hematology</i> , 2009, 84, 62-63.	4.1	16

#	ARTICLE	IF	CITATIONS
55	Rituximab for ITP: A long-term fix?. <i>Pediatric Blood and Cancer</i> , 2009, 52, 155-156.	1.5	1
56	Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1006-1012.	1.5	97
57	Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1072-1075.	1.5	0
58	Mast cell transcriptional networks. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 41, 82-90.	1.4	29
59	The p85 Subunit of Class I Phosphatidylinositol 3-Kinase Regulates the Expression of Multiple Genes Involved in Osteoclast Maturation and Migration. <i>Molecular and Cellular Biology</i> , 2008, 28, 7182-7198.	2.3	31
60	Distinct and Shared Transcriptomes Are Regulated by Microphthalmia-Associated Transcription Factor Isoforms in Mast Cells. <i>Journal of Immunology</i> , 2007, 178, 378-388.	0.8	39
61	Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. <i>Pediatric Blood and Cancer</i> , 2007, 49, 1025-1029.	1.5	29
62	A Large Ribosomal Subunit Protein Abnormality in Diamond-Blackfan Anemia (DBA).. <i>Blood</i> , 2007, 110, 422-422.	1.4	4
63	Kit Signaling Regulates Mitf Expression in Mastocytosis.. <i>Blood</i> , 2006, 108, 3601-3601.	1.4	3
64	Transcriptional Regulation of a Distinct GATA-1 Isoform during Selection of the Mast and Erythroid Lineages.. <i>Blood</i> , 2004, 104, 1600-1600.	1.4	0
65	The Identification and Functional Characterization of a Novel Mast Cell Isoform of the Microphthalmia-associated Transcription Factor. <i>Journal of Biological Chemistry</i> , 2002, 277, 30244-30252.	3.4	71
66	Linkage of M-CSF Signaling to Mitf, TFE3, and the Osteoclast Defect in Mitfmi/mi Mice. <i>Molecular Cell</i> , 2001, 8, 749-758.	9.7	145
67	Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. <i>Human Molecular Genetics</i> , 2000, 9, 125-132.	2.9	150
68	MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. <i>Nature</i> , 1998, 391, 298-301.	27.8	588
69	Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. <i>Pediatric Nephrology</i> , 1998, 12, 654-657.	1.7	31
70	Lineage-specific Signaling in Melanocytes. <i>Journal of Biological Chemistry</i> , 1998, 273, 17983-17986.	3.4	174
71	Age-resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3. <i>Journal of Experimental Medicine</i> , 1998, 187, 775-785.	8.5	88